Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 18, Number 8—August 2012

Research

VIM-2–producing Multidrug-Resistant Pseudomonas aeruginosa ST175 Clone, Spain

Esther Viedma, Carlos Juan, Jennifer Villa, Laura Barrado, M. Ángeles Orellana, Francisca Sanz, Joaquín R. Otero, Antonio Oliver, and Fernando ChavesComments to Author 
Author affiliations: Hospital Universitario 12 de Octubre, Madrid, Spain (E. Viedma, J. Villa, L. Barrado, M.Á. Orellana, F. Sanz, J.R. Otero, F. Chaves); and Hospital Universitario Son Espases, Palma de Mallorca, Spain (C. Juan, A. Oliver)

Main Article

Table A1

Clonal distribution, type of carbapenemase, and drug resistance patterns of MDR Pseudomonas isolates, Spain, January 2007–December 2010 *

Isolate No. isolates/y

Carbapenemase type (no. isolates) ST No. (%) resistant isolates
2007 2008 2009 2010 PIP/TZ CAZ FEP IMP MER ATM GEN TOB AMK CIP
All MDR isolates (183) 13 32 38 100 VIM-1, VIM-2, IMP-22, GES1–5 (146) NA 92 (50.3)/ 180 (98.4) 183 (100) 183 (100) 183 (100) 183 (100) 75 (41.0)/ 179 (97.8)† 178 (97.3) 177 (96.7) 77 (42.1) 172 (94)
P. aeruginosa (clonal types)
B (104) 0 5 23 76 VIM-2 (103), IMP-22 (1) 175, 175 21 (20.2)/ 101 (97.1)† 104 (100) 104 (100) 104 (100) 104 (100) 14 (13.5)/ 100 (95.2)† 104 (100) 104 (100) 26 (25) 104 (100)
A (29)‡ 8 16 4 1 GES 1/5 (29) 235 29 (100) 29 (100) 29 (100) 29 (100) 29 (100) 25 (86.2) 29 (100) 26 (89.6) 25 (86.2) 28 (96.5)
C (2) 0 0 1 1 VIM-2 (2) NA 2 (100) 2 (100) 2 (100) 2 (100) 2 (100) 2 (100) 2 (100) 2 (100) 2 (100) 2 (100)
D (2) 0 0 0 2 Noncarbapenemase (2) NA 2 (100) 2 (100) 2 (100) 2 (100) 2 (100) 0 2 (100) 2 (100) 2 (100) 2 (100)
Unique clones (40) 4 10 8 18 Noncarbapenemase (35) NA 31 (88.6)/ 35 (100)† 35 (100) 35 (100) 35 (100) 35 (100) 26 (74.3) 30 (85.7) 32 (65.7) 17 (48.3) 25 (71.4)
0 1 0 0 PA_5 VIM-2 NA 0 0 0 0 0 0 0 0 0 0
0 1 0 PA_10 VIM-2 NA 0 0 0 0 0 0
0 0 1 0 PA_12 VIM-1 NA 4 (80)/ 5 (100)† 5 (100) 5 (100) 5 (100) 5 (100) 4 (80) 5 (100) 5 (100) 3 (60) 5 (100)
0 0 1 0 PA_13 VIM-2 NA 0 0 0 0 0 0 0 0 0 0
0 0 0 1 PA_28 VIM-2 NA 0 0 0 0 0 0 0 0 0 0
P. putida (clonal types)
Unique clones (6) 1 1 2 2 0 NA 0 0 0 0 0 0 0 0 0 0
1 0 0 0 PP_1 VIM-2 NA 0 0 0 0 0 0 0 0 0 0
0 1 0 0 PP_11 VIM-2 NA 0 0 0 0 0 0 0 0 0 0
0 0 1 0 PP_14 VIM-2 NA 3 (50)/ 6 (100)† 6 (100) 6 (100) 6 (100) 6 (100) 4 (66.6) 6 (100) 6 (100) 2 (33.3) 6 (100)
0 0 1 0 PP_19 VIM-2 NA 0 0 0 0 0 0 0 0 0 0
0 0 1 0 PP25_VIM-1/VIM-2 NA 0 0 0 0 0 0 0 0 0 0
0 0 1 0 PP_27 VIM-2 NA 0 0 0 0 0 0 0 0 0 0

*MDR, multidrug resistant; ST, sequence type; PIP/TZ, piperacillin-tazobactam; CAZ, ceftazidime; FEP, cefepime; IMP, imipenem; MER, meropenem; ATM, aztreonam; GEN, gentamicin; TOB, tobramycin; AMK, amikacin; CIP, ciprofloxacin; NA, not available. None of the isolates showed resistance to colistin.
†Percentage drug-resistant isolates when the European Committee on Susceptibility Testing break point was applied.
‡Viedma et al. (16).

Main Article

TOP